TickerHumSide-by-side comparison
Bristol-Myers Squibb vs Pfizer
As of Nov 11, 2026, P/E is 13.9x for Bristol-Myers Squibb vs 42.1x for Pfizer; P/S is 2.6x for Bristol-Myers Squibb vs 2.6x for Pfizer; revenue growth is 4.2% for Bristol-Myers Squibb vs 1.3% for Pfizer; net margin is 18.5% for Bristol-Myers Squibb vs 6.3% for Pfizer.
What stands out
- Bristol-Myers Squibb is cheaper on earnings: 13.9x P/E vs 42.1x for Pfizer.
- Pfizer carries less debt relative to equity: 0.67 vs 1.79 for Bristol-Myers Squibb.
- Bristol-Myers Squibb scores higher on TickerHum's ratings: 69/100 vs 51/100 for Pfizer.
Key metrics
| Metric | BMY | PFE |
|---|---|---|
| Price | $62.89 | $29.44 |
| Market cap | $128.55B | $167.8B |
| P/E | 13.9x (#1) | 42.1x (#2) |
| P/S | 2.6x (#1) | 2.6x (#2) |
| Revenue growth | 4.2% (#1) | 1.3% (#2) |
| Operating margin | — | — |
| Net margin | 18.5% (#1) | 6.3% (#2) |
| Debt / equity | 1.79 (#2) | 0.67 (#1) |
| 1-year return | +28.1% (#1) | +13.8% (#2) |
| Research score | 69/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General